{
    "clinical_study": {
        "@rank": "107764", 
        "arm_group": [
            {
                "arm_group_label": "240/160/160 mg of UCB4940", 
                "arm_group_type": "Experimental", 
                "description": "240 mg loading dose + 160 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)"
            }, 
            {
                "arm_group_label": "160/80/80 mg of UCB4940", 
                "arm_group_type": "Experimental", 
                "description": "160 mg loading dose + 80 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)"
            }, 
            {
                "arm_group_label": "80/40/40 mg of UCB4940", 
                "arm_group_type": "Experimental", 
                "description": "80 mg loading dose + 40 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)"
            }, 
            {
                "arm_group_label": "560/320/320 mg of UCB4940", 
                "arm_group_type": "Experimental", 
                "description": "560 mg loading dose + 320 mg maintenance dose every 3 weeks on 2 occasions (total 3 doses)"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "0.9% sodium chloride aqueous solution (physiological saline, preservative free) of pharmacopoeia (USP/Ph.Eur) quality in a 10 mL glass vial"
            }
        ], 
        "brief_summary": {
            "textblock": "A study of UCB4940 in subjects with psoriatic arthritis to evaluate the safety and body\n      distribution of UCB4940 in those patients. Neither the patient nor the doctor will know the\n      treatment group."
        }, 
        "brief_title": "Multiple Dose Study of UCB4940 in Subjects With Psoriatic Arthritis", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Psoriatic Arthritis", 
        "condition_browse": {
            "mesh_term": [
                "Arthritis", 
                "Arthritis, Psoriatic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have a diagnosis of adult-onset psoriatic arthritis made at least 6 months prior to\n             Screening as defined by the Classification Criteria for Psoriatic Arthritis\n\n          -  Subject must have active psoriatic lesions or a history of psoriatic skin lesions\n\n          -  Subject must have active arthritis\n\n          -  Subject has had inadequate response to at least 1 nonbiologic Disease-Modifying\n             Antirheumatic Drug (DMARD) (which may include methotrexate [MTX]) and/or 1 approved\n             biologic DMARD\n\n          -  Subject must be taking concurrent MTX for at least 3 months at time of Screening, and\n             be on a stable dose at least 4 weeks prior to Baseline\n\n          -  Female subject must be postmenopausal (at least 1 year), permanently sterilized or,\n             if of childbearing potential, must be willing to use at least 2 effective methods of\n             contraception during the study period\n\n          -  Subject has clinical laboratory test results within the reference ranges of the\n             testing laboratory\n\n          -  Subject has Electrocardiogram (ECG) values within the reference ranges of the testing\n             laboratory\n\n        Exclusion Criteria:\n\n          -  Subject has absolute neutrophil count <1.5\u00d7109/L, and/or lymphocyte count <1.0\u00d7109/L\n\n          -  Subject has known viral hepatitis, has a positive test for hepatitis B surface\n             antigen or is hepatitis C virus antibody positive\n\n          -  Subject tests positive to human immunodeficiency virus (HIV)-1/2 antibody\n\n          -  Subject has a past medical history or family history of primary immunodeficiency\n\n          -  Subject is splenectomized\n\n          -  Subject has had a severe infection requiring hospitalization and/or treatment with iv\n             antibiotics in the 6 months before the Screening Visit\n\n          -  Subject has a history of positive tuberculosis (TB) test or evidence of possible TB\n             or latent TB infection at Screening\n\n          -  Subject has a high risk of acquiring TB infection\n\n          -  Subject has a history of alcoholism or drug/chemical abuse\n\n          -  Subject has an active infection or has had a serious within 6 weeks before the first\n             dose of Investigational Medicinal Product (IMP)\n\n          -  Subject has renal or liver impairment at the Screening Visit\n\n          -  Subject has active neoplastic disease or history of neoplastic disease within 5 years\n             of study entry (except for basal or squamous cell carcinoma of the skin or carcinoma\n             in situ which has been definitively treated with standard of care approaches and is\n             considered cured at Screening)\n\n          -  Subject has any other acute or chronic illness which, in the opinion of the\n             Investigator or Study Physician, could pose a threat or harm to the subject\n\n          -  Subjects must not have a diagnosis of any other inflammatory arthritis, eg,\n             rheumatoid arthritis, sarcoidosis, or systemic lupus erythematosus\n\n          -  Subject has a current or past history of gastrointestinal ulceration\n\n          -  Subjects must not have a noninflammatory condition (eg, osteoarthritis or a known\n             diagnosis of fibromyalgia) that in the Investigator's opinion is symptomatic enough\n             to interfere with evaluation of the effect of IMP on the subject's primary diagnosis\n             of Psoriatic Arthritis (PsA)\n\n          -  Subject has received a live vaccination within 6 weeks before the Screening Visit or\n             intends to have or will need a live vaccination during the course of the study or for\n             the 3 months following last IMP dosing\n\n          -  Subject has had an inadequate response to more than 1 approved biologic\n             Drug-Modifying Antirheumatic Drug (DMARD)\n\n          -  Subject has received any investigational drug or experimental procedure within 90\n             days or 5 half-lives whichever is the longer before the first dose of UCB4940"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "50", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02141763", 
            "org_study_id": "PA0007", 
            "secondary_id": "2013-004949-16"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "80/40/40 mg of UCB4940", 
                    "Placebo"
                ], 
                "description": "Active Substance: UCB4940\nPharmaceutical Form: solution\nConcentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a  final concentration calculated to achieve the correct dose\nRoute of Administration: intravenous", 
                "intervention_name": "UCB4940 40 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "160/80/80 mg of UCB4940", 
                    "80/40/40 mg of UCB4940", 
                    "Placebo"
                ], 
                "description": "Active Substance: UCB4940\nPharmaceutical Form: solution\nConcentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose\nRoute of Administration: intravenous", 
                "intervention_name": "UCB4940 80 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "240/160/160 mg of UCB4940", 
                    "160/80/80 mg of UCB4940", 
                    "Placebo"
                ], 
                "description": "Active Substance: UCB4940\nPharmaceutical Form: solution\nConcentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose\nRoute of Administration: intravenous", 
                "intervention_name": "UCB4940 160 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "240/160/160 mg of UCB4940", 
                    "Placebo"
                ], 
                "description": "Active Substance: UCB4940\nPharmaceutical Form: solution\nConcentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose\nRoute of Administration: intravenous", 
                "intervention_name": "UCB4940 240 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "560/320/320 mg of UCB4940", 
                    "Placebo"
                ], 
                "description": "Active Substance: UCB4940\nPharmaceutical Form: solution\nConcentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose\nRoute of Administration: intravenous", 
                "intervention_name": "UCB4940 320 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "560/320/320 mg of UCB4940", 
                    "Placebo"
                ], 
                "description": "Active Substance: UCB4940\nPharmaceutical Form: solution\nConcentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose\nRoute of Administration: intravenous", 
                "intervention_name": "UCB4940 560 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "240/160/160 mg of UCB4940", 
                    "160/80/80 mg of UCB4940", 
                    "80/40/40 mg of UCB4940", 
                    "560/320/320 mg of UCB4940"
                ], 
                "description": "Pharmaceutical Form: solution\nConcentration: 0.9 % sodium chloride\nRoute of Administration: intravenous", 
                "intervention_name": "Placebo", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": "Psoriatic Arthritis", 
        "lastchanged_date": "May 15, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Sofia", 
                        "country": "Bulgaria"
                    }, 
                    "name": "001"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Chisinau", 
                        "country": "Moldova, Republic of"
                    }, 
                    "name": "002"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }, 
                    "name": "003"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Bulgaria", 
                "Moldova, Republic of", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "5", 
        "official_title": "A Subject-blind, Investigator-blind, Randomized, Placebo-controlled Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of UCB4940 in Subjects With Psoriatic Arthritis", 
        "overall_contact": {
            "last_name": "UCB Clinical Trial Call Center", 
            "phone": "+ 1 877 822 9493"
        }, 
        "overall_official": {
            "affiliation": "UCB, Inc.", 
            "last_name": "UCB Clinical Trial Call Center", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "Bulgaria: Bulgarian Drug Agency", 
                "Moldova: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Day 1: predose; 1 hour (hr), 1.5 hr, 5 hr, 12 hr, 24 hr postdose\nDay 8, 15: 1 sample\nDay 22: predose, 1 hr postdose\nDay 43: predose; 1 hr, 1.5 hr, 5 hr, 12 hr, 24 hr postdose\nDay 48, 57, 64, 85, 141: 1 sample", 
                "measure": "Maximum plasma concentration at steady state (CmaxSS) of UCB 4940 during the duration of the study (up to Day 141)", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Day 141"
            }, 
            {
                "description": "Day 1: predose; 1 hour (hr), 1.5 hr, 5 hr, 12 hr, 24 hr postdose\nDay 8, 15: 1 sample\nDay 22: predose, 1 hr postdose\nDay 43: predose; 1 hr, 1.5 hr, 5 hr, 12 hr, 24 hr postdose\nDay 48, 57, 64, 85, 141: 1 sample", 
                "measure": "Minimum plasma concentration at steady state (CminSS) of UCB4940 during the duration of the study (up to Day 141)", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Day 141"
            }, 
            {
                "description": "Day 1: predose; 1 hour (hr), 1.5 hr, 5 hr, 12 hr, 24 hr postdose\nDay 8, 15: 1 sample\nDay 22: predose, 1 hr postdose\nDay 43: predose; 1 hr, 1.5 hr, 5 hr, 12 hr, 24 hr postdose\nDay 48, 57, 64, 85, 141: 1 sample", 
                "measure": "Area under the curve at steady state (AUCtau) of UCB4940 during the duration of the study (up to Day 141)", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Day 141"
            }, 
            {
                "description": "Day 1: predose; 1 hour (hr), 1.5 hr, 5 hr, 12 hr, 24 hr postdose\nDay 8, 15: 1 sample\nDay 22: predose, 1 hr postdose\nDay 43: predose; 1 hr, 1.5 hr, 5 hr, 12 hr, 24 hr postdose\nDay 48, 57, 64, 85, 141: 1 sample", 
                "measure": "Time to reach maximum plasma concentration at steady state (tmax) of UCB4940 during the duration of the study (up to Day 141)", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Day 141"
            }, 
            {
                "description": "Day 1: predose; 1 hour (hr), 1.5 hr, 5 hr, 12 hr, 24 hr postdose\nDay 8, 15: 1 sample\nDay 22: predose, 1 hr postdose\nDay 43: predose; 1 hr, 1.5 hr, 5 hr, 12 hr, 24 hr postdose\nDay 48, 57, 64, 85, 141: 1 sample", 
                "measure": "Total Clearance (CL) of UCB4940 during the duration of the study (up to Day 141)", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Day 141"
            }, 
            {
                "description": "Day 1: predose; 1 hour (hr), 1.5 hr, 5 hr, 12 hr, 24 hr postdose\nDay 8, 15: 1 sample\nDay 22: predose, 1 hr postdose\nDay 43: predose; 1 hr, 1.5 hr, 5 hr, 12 hr, 24 hr postdose\nDay 48, 57, 64, 85, 141: 1 sample", 
                "measure": "Volume of distribution (V) of UCB4940 during the duration of the study (up to Day 141)", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Day 141"
            }, 
            {
                "measure": "Percentage of subjects with at least one Treatment Emergent Adverse Event (TEAE) during the study", 
                "safety_issue": "No", 
                "time_frame": "From Baseline to Day 141"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02141763"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "UCB, Inc.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Parexel", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "MAC Clinical Research, United Kingdom", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "COMAC, Bulgaria", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "ARENSIA, Moldova", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "UCB Celltech", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}